Complete molecular response in CML after p210 BCR–ABL1-derived peptide vaccination
- 31 August 2010
- journal article
- case report
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 7 (10), 600-603
- https://doi.org/10.1038/nrclinonc.2010.141
Abstract
A 63-year-old woman with chronic myeloid leukemia who achieved a complete cytogenic response after 6 years of interferon-alpha went on to lose molecular response 2 years after treatment cessation. In this Case Study, Monica Bocchia and colleagues demonstrate the positive outcome in this patient following treatment with a therapeutic vaccine that consists of the p210 BCR–ABL1-derived peptide. The patient has maintained a complete molecular response for over 39 months. Background. A 63-year-old woman with chronic myeloid leukemia (CML) received treatment with interferon (IFN)-α for 6 years. After achieving a complete cytogenetic response that was repetitively documented, IFN-α treatment was stopped. Despite maintenance of a complete cytogenetic response, a progressive rise of the BCR–ABL1 transcript was detected and loss of major molecular response occurred about 2 years after stopping IFN-α therapy. Disease remained at molecular level. Investigations. Peripheral blood quantitative real-time PCR every 3 months and periodical bone marrow aspirate were performed to monitor disease. Diagnosis. Chronic-phase, Philadelphia-positive CML that was still detectable after complete cytogenic response 2 years after cessation of IFN-α therapy. Management. The patient was treated with a target immune approach receiving a therapeutic vaccine that consisted of an immunogenic 25-mer b2a2 breakpoint-derived peptide (CMLb2a2–25) with binding properties for several HLA–DR molecules. After nine boosts of vaccine the patient developed an adequate b2a2–25 peptide-specific CD4+ T-cell response and BCR–ABL1 transcript started to decline in peripheral blood. No hematological or extrahematological effects were documented during therapy. At the last evaluation, 39 months since vaccinations commenced, the patient is in complete molecular response with an undetectable level of BCR–ABL1 transcript both in peripheral blood and in bone marrow and she continues to receive boosts of vaccine every 3 months as the only treatment.Keywords
This publication has 16 references indexed in Scilit:
- Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid LeukemiaJournal of Clinical Oncology, 2010
- How I monitor residual disease in chronic myeloid leukemiaBlood, 2009
- Imatinib and beyond—exploring the full potential of targeted therapy for CMLNature Reviews Clinical Oncology, 2009
- Synthetic tumor‐specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual diseaseCancer, 2009
- Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat AnalysisJournal of Clinical Oncology, 2008
- Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC studyLeukemia, 2007
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2006
- Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 yearsBlood, 2006
- Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trialThe Lancet, 2005
- Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic respondersBlood, 2001